- Home
- ARTL vs GLMD Comparison
ARTL vs GLMD Comparison
Compare ARTL & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTL
- GLMD
- Stock Information
- Founded
- ARTL 2011
- GLMD 2000
- Country
- ARTL United States
- GLMD Israel
- Employees
- ARTL N/A
- GLMD N/A
- Industry
- ARTL Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- ARTL Health Care
- GLMD Health Care
- Exchange
- ARTL Nasdaq
- GLMD Nasdaq
- Market Cap
- ARTL 3.1M
- GLMD 3.0M
- IPO Year
- ARTL N/A
- GLMD 2014
- Fundamental
- Price
- ARTL $6.03
- GLMD $1.86
- Analyst Decision
- ARTL Buy
- GLMD Hold
- Analyst Count
- ARTL 2
- GLMD 1
- Target Price
- ARTL $30.00
- GLMD N/A
- AVG Volume (30 Days)
- ARTL 13.2K
- GLMD 341.6K
- Earning Date
- ARTL 08-12-2025
- GLMD 05-22-2025
- Dividend Yield
- ARTL N/A
- GLMD N/A
- EPS Growth
- ARTL N/A
- GLMD N/A
- EPS
- ARTL N/A
- GLMD N/A
- Revenue
- ARTL N/A
- GLMD N/A
- Revenue This Year
- ARTL N/A
- GLMD N/A
- Revenue Next Year
- ARTL N/A
- GLMD N/A
- P/E Ratio
- ARTL N/A
- GLMD N/A
- Revenue Growth
- ARTL N/A
- GLMD N/A
- 52 Week Low
- ARTL $4.92
- GLMD $1.15
- 52 Week High
- ARTL $9.30
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- ARTL 43.05
- GLMD 67.95
- Support Level
- ARTL $6.20
- GLMD $1.53
- Resistance Level
- ARTL $7.35
- GLMD $1.79
- Average True Range (ATR)
- ARTL 0.45
- GLMD 0.10
- MACD
- ARTL -0.09
- GLMD 0.03
- Stochastic Oscillator
- ARTL 0.00
- GLMD 89.36
About ARTL Artelo Biosciences Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.